• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Consumer Cyclical·0926.HK
Share

Besunyen Holdings Company Limited Stocks

HK$ 2.35Last Updated 15.10.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

HK$ 36.62M

HK$ 2.35
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Besunyen Holdings Company Limited, established in Beijing, China, in 2000, functions as a subsidiary of Foreshore Holding Group Limited. The company's core operations encompass the research, development, production, and distribution of therapeutic tea products and pharmaceutical goods throughout the People's Republic of China. Its product range includes a variety of therapeutic teas, prominently featuring the Besunyen brand, alongside specific offerings such as herbal tea, Besunyen Detox, and Besunyen slimming tea. Furthermore, functional teas, such as Besunyen Fit Tea, are also part of its portfolio. Within its pharmaceutical segment, Besunyen markets LARLLY Orlistat for weight loss and manufactures and sells over-the-counter (OTC) medications, including the Besunyen Orlistat weight-loss capsule. Its products reach consumers via an extensive distribution network that includes OTC pharmacies, retail locations in shopping centers and supermarkets, a network of distributors and sub-distributors, and various online e-commerce channels.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, 'cheap'

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.10.2026 22:53

"Ambitions Greater Than Anyone Else's": JPMorgan Expects SpaceX Shares to Triple in Value

21.10.2026 22:20

Berkshire Hathaway shares hit a new record high—for the first time since Buffett announced his retirement

21.10.2026 22:08

A Left or Right Turn: What Investors Are Watching Ahead of the French Presidential Election

21.10.2026 21:10

Shares of Ray-Ban had their best day since 2008. Should you buy them?

21.10.2026 20:20

The Old World on New Chips: How Nvidia Is Driving the Industrial Revolution in Europe

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026